Biofrontera Inc. (BFRI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09077D2099
Biofrontera Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 41.71 m USD |
| Operating income | -11.35 m USD |
| EBIT | -10.51 m USD |
| Net income | -10.54 m USD |
| Diluted EPS – continuing operations | -1.04 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
More stocks
- EDUCATIONAL DEVELOPMENT CORP (EDUC)
- BONK, INC. (BNKK)
- Alpha Star Acquisition Corp (ALSAF)
- HUHUTECH International Group Inc. Ordinary Shares (HUHU)
- OKMIN RESOURCES, INC. (OKMN)
- AMERICAN SHARED HOSPITAL SERVICES (AMS)
- EXICURE, INC. (XCUR)
- Innovative Eyewear Inc (LUCY)
- OXBRIDGE RE HOLDINGS Ltd (OXBR)
- REGIONAL HEALTH PROPERTIES, INC (RHEPZ)
- Rocky Mountain Chocolate Factory, Inc. (RMCF)
- FingerMotion, Inc. (FNGR)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.